Retatrutide benefits in obesity, type 2 diabetes ‘quite staggering’

NEW ORLEANS —A triple receptor agonist provided weight loss for adults with obesity, with or without type 2 diabetes, to an extent not seen with previous pharmacotherapy options, according to data from two phase 3 trials. During a symposium at the American Diabetes Association Scientific Sessions, researchers presented data from phase 3 trials investigating retatrutide (Eli Lilly), a once-weekly